Business · Companies · 29 mins ago
Mayne Pharma agrees to $6.40-a-share takeover by Gedeon Richter
Mayne Pharma has agreed to a cash takeover offer from Gedeon Richter at $6.40 per share.
The Australian drug company’s shares closed at $3.21 on Monday and rose to $5.71 in early trading on Tuesday.
The Mayne board unanimously recommends the offer, and three of the company’s largest shareholders have said they will sell their shares into the deal.
Richter is a specialty drug company founded in Hungary, with operations in about 50 countries.
The offer values Mayne’s equity at about $604 million and follows an earlier bid by US company Cosette, which tried to withdraw before losing a court case and an appeal.
The takeover requires approval from Mayne shareholders and Australia’s foreign investment regulator, as well as a positive recommendation from an independent expert.
Mayne’s board says it would consider a better offer if one emerges before the deal is completed.
Mayne Pharma has agreed to a cash takeover offer from Hungary-based Gedeon Richter worth $6.40 per share.
The offer values Mayne’s equity at about $604 million and has been unanimously recommended by Mayne’s board.
Mayne shareholders must approve the deal, which is also subject to other conditions.
Mayne’s three largest shareholders have indicated they will sell their shares into the deal.
The offer follows a failed takeover bid by Cosette, which had offered $7.40 per share.
- Who
- Mayne Pharma and Gedeon Richter.
- What
- Richter has agreed to acquire Mayne for $6.40 per share in cash.
- When
- The offer was reported on 17 November 2026.
- Where
- Mayne is an Australian pharmaceutical company; Richter is based in Hungary.
- Why
- Not stated.
This story does not have two clearly opposing sides.
Cosette offered to buy Mayne for $7.40 per share.
Mayne said a court had ruled that no material adverse change had occurred and that Mayne had not engaged in misleading or deceptive conduct.
Mayne agreed to Richter’s $6.40-per-share cash offer.
- Offer price
- $6.40 per share in cash
- Deal value
- About $604 million
- Richter’s base
- Hungary
- Mayne board
- Unanimously recommended the offer
- Largest shareholders
- Funicular Funds, Bruce Mathieson and Trium Capital
- Earlier Cosette offer
- $7.40 per share
2 sources
What people are saying
The Board has carefully considered the proposal from Richter and has unanimously concluded that it is in the best interests of Mayne Pharma shareholders, in the absence of a Superior Proposal and subject to the Independent Expert's conclusion.
to realise value at a significant premium to recent trading prices
continue to pursue its claims against Cosette, Cosette Pharmaceuticals Holdings, Inc, and its controllers, Mr David Burghstahler and Avista Capital for damages on behalf of itself and Mayne Pharma shareholders
no Mayne Material Adverse Change had occurred and that Mayne Pharma did not engage in misleading and deceptive conduct regarding its FY25 EBITDA financial performance